Memantine is a medication used to slow the progression of moderate-to-severe Alzheimer's disease.
| FactSnippet No. 624,900 |
10 Facts About Memantine
3.
Memantine is used to treat moderate-to-severe Alzheimer's disease, especially for people who are intolerant of or have a contraindication to AChE inhibitors.
| FactSnippet No. 624,902 |
4.
Memantine has been associated with a modest improvement; with small positive effects on cognition, mood, behavior, and the ability to perform daily activities in moderate-to-severe Alzheimer's disease.
| FactSnippet No. 624,903 |
5.
Memantine when added to donepezil in those with moderate-to-severe dementia resulted in "limited improvements" in a 2017 review.
| FactSnippet No. 624,904 |
6.
Memantine has been investigated as a possible augmentation strategy for depression in bipolar disorder but meta-analytic evidence does not support its clinical utility.
| FactSnippet No. 624,905 |
7.
Memantine appears to be generally well tolerated by children with autism spectrum disorder.
| FactSnippet No. 624,906 |
8.
Memantine is a low-affinity voltage-dependent uncompetitive antagonist at glutamatergic NMDA receptors.
| FactSnippet No. 624,907 |
9.
Memantine was first synthesized and patented by Eli Lilly and Company in 1968 as an anti-diabetic agent, but it was ineffective at lowering blood sugar.
| FactSnippet No. 624,908 |
10.
Memantine was first marketed for dementia in Germany in 1989 under the name Axura.
| FactSnippet No. 624,909 |